"If a PBM is unable to get
a good rebate, then they'll come back and say, 'These guys want a premium and
they're unable to provide a rebate,' so therefore it's a win-win if you don't
put it on the formulary and members have to get the two individual drugs at a
cheaper price."
— Seth Friedman, a health plan services leader at Gallagher
Benefit Services, spoke with AIS's RADAR on Drug Benefits about the rise of
pricey combination therapies in the diabetes space, and how payers negotiate
with drug manufacturers to cover them.
No comments:
Post a Comment